Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00872_DB06335_nanopub.RADY-q6sn1gxRxuhAzFKUvx5mVKax5Fd-F507r16k0x1U#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00872_DB06335 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00872_DB06335 label "DDI between Conivaptan and Saxagliptin - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin. Limit saxagliptin dose to 2.5 mg/day and monitor for increased saxagliptin levels/effects (e.g., hypoglycemia) with concomitant administration of a strong CYP3A4 inhibitor (e.g., ketoconazole). Monitor for decreased saxagliptin levels/effects with discontinuation of concomitant CYP3A4 inhibitor. [drugbank_resource:DB00872_DB06335]" assertion.
- drugbank_resource:DB00872_DB06335 identifier "drugbank_resource:DB00872_DB06335" assertion.
- drugbank_resource:DB00872_DB06335 title "DDI between Conivaptan and Saxagliptin - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin. Limit saxagliptin dose to 2.5 mg/day and monitor for increased saxagliptin levels/effects (e.g., hypoglycemia) with concomitant administration of a strong CYP3A4 inhibitor (e.g., ketoconazole). Monitor for decreased saxagliptin levels/effects with discontinuation of concomitant CYP3A4 inhibitor." assertion.
- drugbank:DB00872 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00872_DB06335 assertion.
- drugbank:DB06335 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00872_DB06335 assertion.